Oncogenic mutants of KRAS, such as the prevalent KRASG12D mutation, have transforming activity and are thought to be founder mutations as they can initiate and drive tumour progression in mouse models (Guerra et al., 2003; Jackson et al., 2001; Sutherland et al., 2014). Here, KRAS is linked to neoplasm.